WVP
XLRN

Worth Venture Partners’s Acceleron Pharma XLRN Stock Holding History

Worth Venture Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,117
Closed -$491K – 192
2018
Q2 		$491K Buy
+10,117
New +$369K 0.41% 36

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Worth Venture Partners's XLRN Position: Q3 2018 in Review

Worth Venture Partners sold out of Acceleron Pharma (XLRN) in Q3 2018, closing a stake of 10,117 shares — an estimated $491K sold.

Worth Venture Partners first reported a position in XLRN in Q2 2018 and held it in 1 quarter. The position peaked at $491K in Q2 2018. 167 funds tracked by Wall St. Rank hold XLRN as of Q3 2018.

  • Worth Venture Partners reported no remaining Acceleron Pharma position as of Q3 2018 after selling out during the quarter.
  • Worth Venture Partners sold 10,117 Acceleron Pharma shares in Q3 2018, an estimated $491K.
  • Worth Venture Partners first reported a position in Acceleron Pharma in Q2 2018 and held it in 1 quarter.
  • Worth Venture Partners's Acceleron Pharma position peaked at $491K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2018.

Based on Worth Venture Partners's 13F filing for Q3 2018, filed 15 Nov 2018.